Days af­ter buy­out news, Vi­for out­lines plan to of­fload 'non-core' fin­ished drug man­u­fac­tur­ing wing

Aus­tralian firm CSL paid a steep price ear­li­er this week for Vi­for Phar­ma and its pipeline of iron and kid­ney drugs. Look­ing to en­sure it starts its next phase as bat­tle-ready as pos­si­ble, Vi­for will now dump its “non-core” man­u­fac­tur­ing busi­ness as it slims down be­fore the merge.

Vi­for Phar­ma will of­fload its fin­ished drug man­u­fac­tur­ing wing to Swiss CD­MO Cor­den­Phar­ma in a deal de­signed to stream­line the biotech’s busi­ness as it awaits reg­u­la­to­ry ap­proval for a $11.7 bil­lion buy­out by CSL an­nounced ear­li­er this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER